Skip to main content
SVBI logo

SVBI — Investor Relations & Filings

Ticker · 1786 ISIN · TW0001786002 TW Manufacturing
Open in API
Filings indexed 1,687 across all filing types
Latest filing 2022-10-06 Director's Dealing
Country TW Taiwan
Listing TW 1786

About SVBI

www.scivision.com.tw

SciVision Biotech Inc. is a specialized developer and manufacturer of advanced medical devices, focusing on the research and production of hyaluronic acid (HA) products. The company leverages its proprietary Crosslinked Hyaluronic Acid Platform (CHAP) technology to create high-performance solutions across multiple medical disciplines. Its core product portfolio includes subcutaneous fillers for facial aesthetics, intra-articular injections for orthopedic joint care, anti-adhesion gels for surgical applications, and vesical instillation solutions for urological treatments. By integrating specialized R&D capabilities with precision manufacturing, SciVision Biotech provides medical-grade HA applications designed to improve patient outcomes in aesthetics and therapeutic recovery. The company is committed to scientific innovation and the expansion of its patented technology to meet diverse clinical needs in the global healthcare market.

Recent filings

Filing Released Lang Actions
111年09月內部人持股異動(事後)
Director's Dealing Classification · 100% confidence The document contains detailed tabular data about shareholdings of company insiders, including directors, managers, and their related parties. It lists share types, holdings at different times, increases and decreases in holdings, and other related information. This type of document is characteristic of a Director's Dealing report, which discloses personal share transactions by company directors and executives. There is no indication of financial statements, earnings data, or meeting materials. The document is not an announcement of a report but the actual disclosure of insider shareholdings and transactions. Therefore, the appropriate classification is Director's Dealing (DIRS).
2022-10-06 Chinese
111年09月董事會成員及持股
Director's Dealing Classification · 95% confidence The document contains detailed tables listing shareholdings of company insiders, including directors and senior management, with specific numbers of shares held, pledged shares, and related information. The content focuses on insider shareholdings and their changes, which aligns with the category of Director's Dealing (DIRS). The document length is 2491 characters, which is relatively short but contains substantive data on insider shareholdings rather than just an announcement or certification. There is no indication of financial results, audit information, or other report types. Therefore, the document is best classified as a Director's Dealing report.
2022-10-06 Chinese
公告本公司國內第二次無擔保轉換公司債收足應募價款
Capital/Financing Update Classification · 95% confidence The document is a short announcement from a company (科妍生物科技股份有限公司) regarding the receipt of subscription funds for its second domestic unsecured convertible bonds, totaling NT$400,000,000. It references compliance with securities issuance regulations and provides factual details about the transaction date and amount. The content is focused on a capital raising event and does not contain financial statements or detailed financial analysis. The document length is only 652 characters, indicating it is a brief announcement rather than a full report. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2022-09-29 Chinese
公告本公司國內第二次無擔保轉換公司債完成訂價
Capital/Financing Update Classification · 95% confidence The document is a short announcement (759 characters) from a company about the pricing of its second domestic unsecured convertible bonds. It includes specific details about the bond pricing and regulatory approval references but does not contain financial statements or detailed financial analysis. It is an update on a capital market activity related to bond issuance and pricing. Given the content and length, this fits best under Capital/Financing Update (CAP) rather than a full financial report or regulatory filing. The document is not a report publication announcement or a certification, but a direct announcement of a financing event.
2022-09-23 Chinese
公告本公司國內第二次無擔保轉換公司債代收價款合約及存 儲專戶合約
Capital/Financing Update Classification · 95% confidence The document is a short announcement (663 characters) from a listed company regarding a contract related to the collection and storage of funds for a domestic unsecured convertible bond. It references compliance with securities issuance regulations but does not contain financial statements or detailed financial data. It is not a full report but an announcement of a contractual arrangement related to financing activities. Therefore, it fits best under Capital/Financing Update (CAP).
2022-09-15 Chinese
111年8月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a financial disclosure from a listed company (科妍) providing information about fund loans and endorsement guarantees for the current and previous month, with amounts all zero. It is a regulatory disclosure of financial status related to guarantees and loans, typical of a regulatory filing rather than a full report or announcement. The document is short (601 characters) and contains tabular financial data but no comprehensive financial statements or management discussion. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is best classified as a Regulatory Filing (RNS) as it is a routine compliance disclosure without detailed financial analysis or report publication announcement.
2022-09-07 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.